ロード中...
Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
Introduction Cetuximab is registered for use in colorectal cancer (CRC) patients with RAS wild-type tumours only. Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification (prenylation) of KRAS. We hypothesize that the activitated KRAS pathway in KRAS...
保存先:
| 出版年: | Invest New Drugs |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4648966/ https://ncbi.nlm.nih.gov/pubmed/26386973 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0285-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|